Patents by Inventor Alan Kraker

Alan Kraker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of checkpoint kinases (Wee1 and Chk1)
    Patent number: 7094798
    Abstract: This invention relates to pyrrolocarbazole derivatives according formula I wherein R1, R2, R7, R8, R9, X and Y are as defined in the specification wherein said derivatives specifically inhibit one or both of the checkpoint kinases Wee1 and Chk1
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: August 22, 2006
    Assignee: Pfizer Inc
    Inventors: Richard John Booth, Ellen Myra Dobrusin, Alan Kraker, Lorna Helen Mitchell, William Alexander Denny, Jeffrey Bruce Smaill, Andrew Mark Thompson, Florence Oliver Joseph McCarthy, Ho Huat Lee, Brian Desmond Palmer
  • Inhibitors of checkpoint kinases (Wee1 and Chk1)
    Publication number: 20050250836
    Abstract: This invention relates to substituted indacene molecules that specifically inhibit one or both of the checkpoint kinases Wee1 and Chk1 and are useful in the treatment of proliferative disorders.
    Type: Application
    Filed: May 2, 2005
    Publication date: November 10, 2005
    Inventors: Richard Booth, Ho Lee, Alan Kraker, Daniel Ortwine, Brian Palmer, Derek Sheehan, Peter Toogood
  • Modified Wee1, crystals of peptide: inhibitor complexes containing such modified Wee1, and methods of use thereof
    Publication number: 20050037476
    Abstract: Modified Wee1 peptides, polynucleotides encoding those peptides, and methods for purifying the peptides and crystallizing them as peptide: inhibitor complexes have been discovered. The three-dimensional structure of Wee1, including the ATP substrate binding site, and uses of this information in the design and screening of compounds that may associate with Wee1, or peptides structurally related thereto, have also been discovered.
    Type: Application
    Filed: May 4, 2004
    Publication date: February 17, 2005
    Inventors: Edward Baker, Richard Booth, Alan Kraker, Daniel Ortwine, James Dickson, Ivan Ivanovic, Christopher Squire
  • Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
    Publication number: 20030186987
    Abstract: Described are heterocyclic pyrimidine derivatives and a method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of the formula: 1
    Type: Application
    Filed: July 24, 2002
    Publication date: October 2, 2003
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson
  • Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
    Patent number: 6596726
    Abstract: Described are compounds of the following formula and a method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of the formula: wherein the formula terms are described in the specification and wherein the members in the aforementioned structure are defined in the specification.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: July 22, 2003
    Assignee: Warner Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson, Howard Daniel Hollis Showalter
  • Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
    Patent number: 6455534
    Abstract: Described are compounds and a method of inhibiting epidermal growth factor receptor tyrosine kinase by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of Formula II: where: one of A or E is nitrogen, with remaining atoms carbon; X=O, S, NH or NR7, such that R7=lower alkyl (1-4 carbon atoms), OH, NH2, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms). Other terms are described in the specification.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: September 24, 2002
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson
  • Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
    Publication number: 20010027197
    Abstract: Described are compounds and a method of inhibiting epidermal growth factor receptor tyrosine kinase by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of Formula II: 1
    Type: Application
    Filed: April 2, 2001
    Publication date: October 4, 2001
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson
  • Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
    Patent number: 6265410
    Abstract: Described are compositions and a method of inhibiting epidermal growth factor receptor tyrosine kinase by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of Formula II: where: any two continguous positions in positions A-E taken together can be a single heteroatom selected from the group consisting of nitrogen, oxygen or sulfur, in which case the other two remaining atoms must be carbon; the remaining substituents are disclosed in the specification
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: July 24, 2001
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson
  • Substituted pyrido[3,2-d]pyrimidines capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
    Patent number: 6084095
    Abstract: Novel 4-substituted amino pyrido [3,2-d]pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinases are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: July 4, 2000
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson
  • Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
    Patent number: 5679683
    Abstract: Novel 4-substituted amino benzothieno?3,2-d!pyrimidine and 4-substituted amino?2,3-d!pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinases are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: October 21, 1997
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson, Howard Daniel Hollis Showalter
  • Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
    Patent number: 5654307
    Abstract: Novel 4-substituted amino pyrido pyrimidine and 4-substituted amino pyrido pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinase are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: August 5, 1997
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson